Kotaro Suzuki

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 8

Top Topics

Diabetic Nephropathy

Interstitial Lung Disease

Systemic Lupus Erythematosus

Top Venues

Nature communications

Lupus science & medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Hiroki Furuya, Yosuke Toda, Arifumi Iwata, Mizuki Kanai, Kodai Kato, Takashi Kumagai, Takahiro Kageyama, Shigeru Tanaka, Lisa Fujimura, Akemi Sakamoto, Masahiko Hatano, Akira Suto, Kotaro Suzuki, Hiroshi Nakajima
Stage-specific GATA3 induction promotes ILC2 development after lineage commitment. Nature communications 15 (1) (2024)
Hiroki Furuya, Yosuke Toda, Arifumi Iwata, Mizuki Kanai, Kodai Kato, Takashi Kumagai, Takahiro Kageyama, Shigeru Tanaka, Lisa Fujimura, Akemi Sakamoto, Masahiko Hatano, Akira Suto, Kotaro Suzuki, Hiroshi Nakajima
Stage-specific GATA3 induction promotes ILC2 development after lineage commitment. Nature communications 15 (1) (2024)
Hiroki Furuya, Yosuke Toda, Arifumi Iwata, Mizuki Kanai, Kodai Kato, Takashi Kumagai, Takahiro Kageyama, Shigeru Tanaka, Lisa Fujimura, Akemi Sakamoto, Masahiko Hatano, Akira Suto, Kotaro Suzuki, Hiroshi Nakajima
Stage-specific GATA3 induction promotes ILC2 development after lineage commitment. Nature communications 15 (1) (2024)
Tomoaki Ida, Shunsuke Furuta, Asuka Takayama, Jun Tamura, Yuki Hayashi, Kazuya Abe, Syunjiro Kurihara, Junichi Ishikawa, Taro Iwamoto, Kei Ikeda, Kotaro Suzuki, Hiroshi Nakajima
Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis. RMD open 9 (1) (2023)
Tomoaki Ida, Shunsuke Furuta, Asuka Takayama, Jun Tamura, Yuki Hayashi, Kazuya Abe, Syunjiro Kurihara, Junichi Ishikawa, Taro Iwamoto, Kei Ikeda, Kotaro Suzuki, Hiroshi Nakajima
Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis. RMD open 9 (1) (2023)
Tomoaki Ida, Shunsuke Furuta, Asuka Takayama, Jun Tamura, Yuki Hayashi, Kazuya Abe, Syunjiro Kurihara, Junichi Ishikawa, Taro Iwamoto, Kei Ikeda, Kotaro Suzuki, Hiroshi Nakajima
Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis. RMD open 9 (1) (2023)
Tomoaki Ida, Shunsuke Furuta, Asuka Takayama, Jun Tamura, Yuki Hayashi, Kazuya Abe, Syunjiro Kurihara, Junichi Ishikawa, Taro Iwamoto, Kei Ikeda, Kotaro Suzuki, Hiroshi Nakajima
Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis. RMD open 9 (1) (2023)
Masashi Fukuta, Kotaro Suzuki, Shotaro Kojima, Yoko Yabe, Kazumasa Suzuki, Kazuma Iida, Hiroyuki Yamada, Shinichi Makino, Arifumi Iwata, Shigeru Tanaka, Taro Iwamoto, Akira Suto, Daiki Nakagomi, Hidefumi Wakashin, Yuko Maezawa, Yoshiro Maezawa, Minoru Takemoto, Katsuhiko Asanuma, Hiroshi Nakajima
Suppressor of cytokine signalling 3 (SOCS3) expressed in podocytes attenuates glomerulonephritis and suppresses autoantibody production in an imiquimod-induced lupus model. Lupus science & medicine 8 (1) (2021)